These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 11328982)

  • 21. Definition of a well-characterized biotechnology product.
    Zoon K; Garnick R
    Dev Biol Stand; 1998; 96():191-7. PubMed ID: 9890531
    [No Abstract]   [Full Text] [Related]  

  • 22. Monoclonal antibodies: production, uses and side effects.
    Cowden J; Parker SK
    Pediatr Infect Dis J; 2006 Jun; 25(6):553-5. PubMed ID: 16732156
    [No Abstract]   [Full Text] [Related]  

  • 23. Reflections on historical, scientific, and legal issues relevant to designing approval pathways for generic versions of recombinant protein-based therapeutics and monoclonal antibodies.
    Dudzinski DM
    Food Drug Law J; 2005; 60(2):143-260. PubMed ID: 16094771
    [No Abstract]   [Full Text] [Related]  

  • 24. Fake biotech drugs raise concerns.
    Fox JL
    Nat Biotechnol; 2001 Jul; 19(7):603. PubMed ID: 11433258
    [No Abstract]   [Full Text] [Related]  

  • 25. Natalizumab (Tysabri) returns.
    Med Lett Drugs Ther; 2006 Sep; 48(1243):76. PubMed ID: 16977289
    [No Abstract]   [Full Text] [Related]  

  • 26. Western biotechs ponder follow-on possibilities.
    Waltz E
    Nat Biotechnol; 2008 Sep; 26(9):962-3. PubMed ID: 18779793
    [No Abstract]   [Full Text] [Related]  

  • 27. Biotechnology, cost concerns dominate in 1989.
    Souhrada L
    Hospitals; 1989 Dec; 63(24):32. PubMed ID: 2591898
    [No Abstract]   [Full Text] [Related]  

  • 28. HHS: POUFA reauthorization good for Americans.
    FDA Consum; 2002; 36(5):5. PubMed ID: 12412536
    [No Abstract]   [Full Text] [Related]  

  • 29. [Monoclonal antibodies and therapeutics].
    Desgranges C
    Pathol Biol (Paris); 2004 Jul; 52(6):351-64. PubMed ID: 15261379
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Stromedix acquisition signals growing interest in fibrosis.
    Allison M
    Nat Biotechnol; 2012 May; 30(5):375-6. PubMed ID: 22565944
    [No Abstract]   [Full Text] [Related]  

  • 31. Off-label uses of monoclonal antibodies for treatment of B-cell lymphoid or myeloid malignancies.
    Tecnologica MAP Suppl; 2001 Jul; ():14-7. PubMed ID: 11718149
    [No Abstract]   [Full Text] [Related]  

  • 32. Human antibodies from transgenic animals.
    Lonberg N
    Nat Biotechnol; 2005 Sep; 23(9):1117-25. PubMed ID: 16151405
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Biotech jostles with pharma for slice of HIV market.
    Katsnelson A
    Nat Biotechnol; 2006 Jan; 24(1):3-4. PubMed ID: 16404375
    [No Abstract]   [Full Text] [Related]  

  • 34. Products of new biotechnologies.
    FDA Drug Bull; 1986 Nov; 16(2):19. PubMed ID: 2950012
    [No Abstract]   [Full Text] [Related]  

  • 35. Exploring emerging nanobiotechnology drugs and medical devices.
    Paradise J; Diliberto GM; Tisdale AW; Kokkoli E
    Food Drug Law J; 2008; 63(2):407-20. PubMed ID: 18561467
    [No Abstract]   [Full Text] [Related]  

  • 36. Bioterrorism--biotechnology to the rescue?
    Niiler E
    Nat Biotechnol; 2002 Jan; 20(1):21-5. PubMed ID: 11753354
    [No Abstract]   [Full Text] [Related]  

  • 37. Private company profiles.
    Nat Biotechnol; 2003 Jul; 21 Suppl():BE23-8. PubMed ID: 12874973
    [No Abstract]   [Full Text] [Related]  

  • 38. Rethinking US leadership in food biotechnology.
    Taylor MR
    Nat Biotechnol; 2003 Aug; 21(8):852-4. PubMed ID: 12894194
    [No Abstract]   [Full Text] [Related]  

  • 39. The biotechnology industry: What's next?
    Guertin PA
    Biotechnol J; 2009 Aug; 4(8):1124-31. PubMed ID: 19685466
    [No Abstract]   [Full Text] [Related]  

  • 40. Real and metaphorical moral limits in the biotech debate.
    Saner MA
    Nat Biotechnol; 2001 Jul; 19(7):609. PubMed ID: 11433262
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.